newsfilter
← Latest News
GlobeNewswire·

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations